This Month in AJP  by unknown
The American Journal of Pathology, Vol. 179, No. 2, August 2011
Copyright © 2011 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2011.05.030This Month in AJPSeeing Deeper Leads to Deeper Understanding
The early detection of internal organ disease is critical to
accurate diagnosis, management, or cure. Magnetic reso-
nance (MR) imaging has aided the transformation of diag-
nosis in vivo; however, this technology is limited by low
resolution. Grippo et al (Am J Pathol 2011, 179:610–618)
used high-field-strength MR without contrast agents to
visualize acini, islets, and blood vessels of ex vivo murine
pancreata. High-field-strength MR results corresponded
well with established criteria obtained by histology and
the compiling of 2D images into a 3D image set. Such
improvements to imaging technology may, in the future,
lead to more accurate diagnoses and treatment.
A New Model for Testing Pulmonary Disease
Obliterative bronchiolitis is a life-threatening disease that
may develop subsequent to lung transplantation. A new
report by Xue et al (Am J Pathol 2011, 179:745–753)
describes development and validation of a model that
utilizes both human lung tissue and human effector cells.
Lung explants from human cadavers were transplanted
into NOD/SCID mice, followed by adoptive transfer of
allogeneic human T cells. Three weeks after implantation,
the lung tissue showed evidence of inflammatory cell
infiltration, and one week later, tissue exhibited extensive
damage (ie, loss of airway epithelium and obliteration of
airway lumens). This model provides a promising oppor-
tunity to evaluate the ability of immunosuppressants to
delay the onset of disease.
Activating Different TLRs Produces Different
Outcomes in the Brain
The Toll-like receptors (TLRs) are active in the innate
immune response, and each recognizes a different, spe-
cific component of bacteria or viruses. Whereas TLR7
recognizes single-strand RNA (and the agonist imi-
quimod) and TLR9 binds to oligonucleotides lacking
methylation at CpG sites (CpG-ODN), both receptors
share signaling pathway components. Butchi et al (Am J
Pathol 2011, 179:783–794) examined the ability of TLR7
and TLR9 agonists to mediate neuroinflammation. Imi-
quimod-activated TLR7 elicited a weak inflammatory re-
sponse compared to that of CpG-ODN-mediated TLR9,which effected significantly larger releases of cytokines
(ie, IL-12 p40 and tumor necrosis factor) and a break-
down of the blood-CSF barrier, leading to infiltration of the
CNS by peripheral cells. Choroid plexus cells are sur-
mised to broker the increase in cytokine production
brought on by TLR9 activation. These findings indicate
that proper drug choice, insofar as TLR responses are
concerned, is critical to ameliorating neuroinflammation.
Follistatin Improves Skeletal Muscle Healing
Fibrosis and inadequate myofiber regeneration fre-
quently hamper recovery from skeletal muscle injury. In
an effort to identify therapies that both stimulate muscle
regeneration and inhibit fibrosis, Zhu et al (Am J Pathol
2011, 179:915–930) investigated follistatin, an antagonist
of the TGF- superfamily member myostatin. After skele-
tal muscle injury, follistatin-overexpressing transgenic
mice displayed significantly greater myofiber regenera-
tion and less fibrosis formation compared to wild-type
mice. Furthermore, isolated muscle progenitor cells
showed improved regeneration of dystrophin-positive
myofibers when transplanted into the skeletal muscle of
mdx/SCID mice. In vitro, follistatin stimulated myoblasts to
express the myogenic transcription factors MyoD, Myf5,
and myogenin. Thus, follistatin may be beneficial for a
variety of skeletal muscle injuries and disorders, such as
muscular dystrophies.
Cutting the Effect of Fat in Breast Cancer
Obesity conveys significant risk for breast cancer, and
the adipocyte-expressed cytokine leptin plays a crucial
role. Catalano et al (Am J Pathol 2011, 179:1030–1040)
evaluated the ability of peroxisome proliferator-activated
receptor-gamma (PPAR) ligands to counteract leptin
stimulatory effects on breast cancer growth. PPAR ac-
tivation prevented the development of leptin-induced
MCF-7 tumor xenografts in mice and inhibited cell-cell
aggregation and proliferation. PPAR ligands also abro-
gated upregulated gene expression of leptin and its re-
ceptors, inhibited leptin signaling mediated by MAPK/
STAT3/Akt phosphorylation, and counteracted leptin’s
stimulatory effects on estrogen signaling. These results
highlight the possible therapeutic benefits of PPAR li-
gands in the treatment of breast cancer.
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